The Global Anticoagulants Market was valued at $24.2 billion in 2017, and is projected to cross $43.4 Billion by 2025, growing at a CAGR of 7.5% from 2018 to 2025, according to a new report published by Allied Market Research.
Anticoagulants are medicinal substances that reduce the coagulation of blood and prolong the clotting time. Anticoagulant drugs achieve their effects by suppressing the synthesis or function of various clotting factors that exist in the blood. The global anticoagulants market is anticipated to show significant market growth during the forecast period, owing to increase in prevalence of ischemic heart disease and venous thromboembolism (VTE) and awareness of novel oral anticoagulants (NOACs). In addition, increasing number of geriatric population and growing incidence of obese population is expected to further increase the demand for anticoagulants throughout the forecast period. On the other side, very high cost of NOACs is expected to negatively affect the growth of the anticoagulants market.
Download Sample Copy of this Report at https://www.alliedmarketresearch.com/request-sample/1673
North America accounted approximately one-half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. This was attributed to the higher demand for novel therapeutics, strong presence of key players, early diagnosis, developed healthcare infrastructure, presence of trained medical professionals, and larger target population. However, the Asia-Pacific region is expected to experience the highest growth rate during the forecast period, majorly owing to improving healthcare infrastructure with developing economies, rising diagnosis rate, enhancing health awareness, and increasing prevalence of cardiovascular disease and VTE.
On the basis of drug class, the anticoagulants market is segmented as NOACs, heparin & LMWH, vitamin K antagonist, and others. At present, the NOACs segment is a major revenue-generating segment and is anticipated to show dominance during the forecast period, owing to growing awareness of NOACs and rising use of NOACs over the warfarin. However, higher price of NOACs hinders the market growth. As per the route of administration, the anticoagulants market is segmented as oral anticoagulant and injectable anticoagulant. At present, the oral anticoagulant segment is a major revenue-generating segment and is anticipated to show dominance during the forecast period, owing to growing adoption of NOACs and rising availability of lower cost warfarin.
The application market is categorized as atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. Presently, the atrial fibrillation & heart attack segment is a major revenue contributor and is anticipated to show dominance throughout the forecast period, owing to large target population and increase in use of anticoagulants to treat these conditions. However, the DVT segment is expected to show the fastest market growth, attributed to the increase in prevalence of DVT and technological advancement in diagnosis of DVT.
Check available discounts on this report at https://www.alliedmarketresearch.com/purchase-enquiry/1673
Anticoagulants Market Key Findings:
- As per the drug class, the NOACs segment is expected to show the fastest market growth and grow at a CAGR of 8.0% from 2018 to 2025.
- On the basis of the route of administration, the oral anticoagulant segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
- By application, the deep vein thrombosis (DVT) segment is expected to exhibit the fastest growth at a CAGR of 8.4% from 2018 to 2025.
- Region-wise, the Asia-Pacific region is expected to experience growth at the highest rate, registering a CAGR of 9.2% during the forecast period.
Scope of the Report:
| Report Attribute | Details |
| Market size available for years | 2018 – 2025 |
| Base year considered | 2019 |
| Forecast period | 2018 – 2025 |
| Forecast units | Value (USD) |
| Segments covered | By Drug Class, Route of Administration, and Application |
| Geographies covered | North America, Europe, Asia-Pacific, LAMEA |
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com